G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.
The VICTORION-2-PREVENT trial is taking place at the Gordon and Leslie Diamond Health Care Centre at the University of British Columbia and is currently in the recruiting process. The trial’s main objective is to provide evidence in favor of using inclisiran to lower cardiovascular risk in individuals who already have atherosclerotic cardiovascular disease (ASCVD) and elevated levels of low-density lipoprotein (LDL) cholesterol, despite being on a well-tolerated high-intensity statin therapy. Participants will be followed for 72 months.
G.B. John Mancini, MD, professor of medicine and director of the Cardiovascular Imaging Research Core Laboratory at the University of British Columbia, scientific director of the Cardio Risk Clinic, is the principal investigator (PI) of the VICTORION-2-PREVENT trial. Here, he details some of the criteria and recruiting process of the trial, and addresses the lack of women in CVD research and how he aims to avoid this issue in the trial.
Transcript
Can you tell us about the VICTORION-2-PREVENT trial involving inclisiran?
The VICTORION-2 trial is using the interesting technology of inclisiran, which is injected at baseline and then 3 months, and then after that it's only 2 injections a year, every 6 months. So, it's very attractive in that regard, in terms of the burden of injection, and it results in a sustained 50% lowering of LDL.
The trial is very exciting. It's in secondary prevention settings, so patients with prior MI [myocardial infarction] or stroke, or with symptomatic peripheral vascular disease. It's going to be huge—over 16,000 patients—and we've been recruiting well across Canada. The Canadian PIs are Drs [Liam] Brunham and [Shaun] Goodman. And we've had good success in getting our colleagues to support the recruitment of these kinds of patients who were on statins and their LDL is, in millimolar, above 1.8. That's about 80 in milligrams per deciliter. It's an outcome trial and event driven, so it'll be very impactful in terms of the ultimate utility of inclisiran for reducing cardiovascular risk.
What steps are you taking during recruitment to ensure a representative patient population that can be followed for all 72 months?
We have, in our setting, a group of very dedicated research nurses and research associates that scour all the patient records for us and engage all of the clinicians in our environment to encourage them to enroll appropriate patients, if the inclusion criteria are met, obviously. We particularly hope to have a good representation of women in this trial, as is often a limitation of many cardiovascular trials. Really, it's a full court press in terms of all of the patients that come through our clinics.
Why is it difficult to recruit women for CVD trials?
The overall risk for women, and therefore the presentation of numbers of patients, is a little bit lower for women, so there is a systematic reason for that. But beyond that, many women have different social pressures, and the ability to accommodate frequent visits or blood tests and so on may be quite different between the sexes. Those are a few of the reasons that come to mind as to why, traditionally, these cardiovascular trials have been dominated by men. We hope that's not the case. We've seen examples where it has not been the case, and we hope to emulate that as much as possible in all the trials we're doing.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More